Loading…
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $107M | $135M | $106M | $238M | 35.7% | 66.9% | -287.7% |
| 2024 | $64M | $-38M | $-56M | $-12M | -32.1% | 12.1% | 2.2% |
| 2023 | $57M | $-43M | $-55M | $-29M | -25.9% | 11.8% | -106.3% |
| 2022 | $51M | $-79M | $872M | $-188M | 197.4% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 51.35 | 57.42 | 64.38 | 107.46 |
| Operating Revenue | - | 51.35 | 57.42 | 64.38 | 107.46 |
| Operating Expense | - | 130.46 | 110.72 | 106.82 | 111.07 |
| Research And Development | - | 63.39 | 40.62 | 37.64 | 37.41 |
| Selling General And Administration | - | 67.07 | 70.10 | 69.17 | 73.65 |
| Total Expenses | - | 130.46 | 110.72 | 106.82 | 111.07 |
| Operating Income | - | -79.12 | -53.29 | -42.44 | -3.60 |
| Total Operating Income As Reported | - | -91.96 | -56.04 | -46.95 | -3.60 |
| EBITDA | - | -79.42 | -42.66 | -38.45 | 134.52 |
| Normalized EBITDA | - | -63.55 | -39.92 | -33.94 | 59.38 |
| EBIT | - | -86.45 | -46.92 | -42.07 | 131.71 |
| Interest Income | - | 8.54 | 9.12 | 4.88 | 10.17 |
| Interest Expense | - | 6.37 | 2.35 | 2.55 | 2.46 |
| Net Interest Income | - | 2.18 | 6.77 | 2.34 | 7.71 |
| Other Non Operating Income Expenses | - | - | - | - | 50 |
| Other Income Expense | - | -15.87 | -2.74 | -4.51 | 125.14 |
| Interest Income Non Operating | - | 8.54 | 9.12 | 4.88 | 10.17 |
| Interest Expense Non Operating | - | 6.37 | 2.35 | 2.55 | 2.46 |
| Net Non Operating Interest Income Expense | - | 2.18 | 6.77 | 2.34 | 7.71 |
| Pretax Income | - | -92.82 | -49.27 | -44.61 | 129.25 |
| Tax Provision | - | 0.01 | 5.92 | 11.80 | 23.35 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -3.33 | -0.58 | -0.95 | 13.58 |
| Net Income Continuous Operations | - | -92.82 | -55.19 | -56.42 | 105.90 |
| Net Income From Continuing And Discontinued Operation | - | 872.13 | -55.19 | -56.42 | 105.90 |
| Net Income From Continuing Operation Net Minority Interest | - | -92.82 | -55.19 | -56.42 | 105.90 |
| Net Income | - | 872.13 | -55.19 | -56.42 | 105.90 |
| Net Income Common Stockholders | - | 872.13 | -55.19 | -56.42 | 105.90 |
| Net Income Including Noncontrolling Interests | - | 872.13 | -55.19 | -56.42 | 105.90 |
| Normalized Income | - | -80.29 | -53.03 | -52.85 | 44.34 |
| Diluted NI Availto Com Stockholders | - | 872.13 | -55.19 | -56.42 | 105.90 |
| Basic Average Shares | - | 73.59 | 55.30 | 48.85 | 50.32 |
| Diluted Average Shares | - | 73.59 | 55.30 | 48.85 | 51.51 |
| Reconciled Depreciation | - | 7.02 | 4.26 | 3.62 | 2.81 |
| Total Unusual Items | - | -15.87 | -2.74 | -4.51 | 75.14 |
| Total Unusual Items Excluding Goodwill | - | -15.87 | -2.74 | -4.51 | 75.14 |
| Net Income Discontinuous Operations | 65.64 | 964.96 | 0 | - | - |
| Special Income Charges | - | -15.87 | -2.74 | -4.51 | 75.14 |
| Other Special Charges | - | 3.03 | - | - | - |
| Impairment Of Capital Assets | - | - | 0 | 4.51 | 0 |
| Restructuring And Mergern Acquisition | 20.14 | 12.84 | 2.74 | 0 | - |
| Gain On Sale Of Ppe | - | - | - | 0 | 75.14 |
| Earnings From Equity Interest | 103.99 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Theravance Biopharma, Inc.this co. | TBPH | $844M | 7.97 | 2.84 | 35.7% | 5.34 |
| Certara, Inc. | CERT | $873M | -547.16 | 0.82 | -0.2% | 9.65 |
| Talkspace, Inc. | TALK | $871M | 111.78 | 7.44 | 6.7% | 129.10 |
| Arbutus Biopharma Corporation | ABUS | $859M | -25.65 | 11.22 | -43.7% | -25.48 |
| Janux Therapeutics, Inc. | JANX | $839M |
| - |
| - |
| - |
| - |
| - |
| - |
| -7.39 |
| 0.88 |
| -11.9% |
| -5.20 |
| ORIC Pharmaceuticals, Inc. | ORIC | $830M | -6.41 | 2.16 | -33.7% | -5.56 |
| LB Pharmaceuticals Inc | LBRX | $829M | -32.88 | 2.75 | -8.4% | -19.35 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Sana Biotechnology, Inc. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Peer Median | - | -6.90 | 2.46 | -10.1% | -4.75 | |